ALEXION PHARMACEUTICALS
Alexion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). In April 2... 009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. Or the production of Soliris.
ALEXION PHARMACEUTICALS
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
1992-01-01
Address:
Cheshire, Connecticut, United States
Country:
United States
Website Url:
http://www.alexion.com
Total Employee:
1001+
Status:
Active
Contact:
(203) 272-2596
Email Addresses:
[email protected]
Total Funding:
5.8 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Domain Not Resolving SSL By Default Google Tag Manager Apple Mobile Web Clips Icon Google Font API HSTS LetsEncrypt Mobile Non Scaleable Content
Similar Organizations
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
AVEO Oncology
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
Connetics
Connetics Corporation engages in the development and commercialization of products for the medical dermatology market.
Mallinckrodt
Their evolution as a company starts now, and they are poised for an exciting future. Their core strengths provide the impetus for future
Merck
Merck is a biopharmaceutical company that offers medicines and vaccines for various diseases.
Merz Pharma
Merz Pharmaceuticals is an innovative pharmaceutical company specializing in the research and marketing of drugs for the treatment of
PTC Therapeutics
PTC Therapeutics is a biopharmaceutical company that engages in the discovery, development and commercialization of small-molecule drugs.
Quinnova Pharmaceuticals
Quinnova Pharmaceuticals is a biotech company engaged in the development and commercialization of prescription drug products.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-10-03 | LogicBio Therapeutics | LogicBio Therapeutics acquired by Alexion Pharmaceuticals | 70 M USD |
| 2020-05-05 | Portola Pharmaceuticals | Portola Pharmaceuticals acquired by Alexion Pharmaceuticals | 1.4 B USD |
| 2019-10-16 | Achillion Pharmaceuticals | Achillion Pharmaceuticals acquired by Alexion Pharmaceuticals | N/A |
| 2018-09-26 | Syntimmune | Syntimmune acquired by Alexion Pharmaceuticals | 1.2 B USD |
| 2018-04-11 | Wilson Therapeutics | Wilson Therapeutics acquired by Alexion Pharmaceuticals | N/A |
| 2015-05-06 | Synageva BioPharma | Synageva BioPharma acquired by Alexion Pharmaceuticals | 8.4 B USD |
| 2011-12-29 | Enobia Pharma | Enobia Pharma acquired by Alexion Pharmaceuticals | N/A |
| 2011-01-31 | Taligen Therapeutics | Taligen Therapeutics acquired by Alexion Pharmaceuticals | 111 M USD |
| 2000-09-25 | Prolifaron | Prolifaron acquired by Alexion Pharmaceuticals | 41 M USD |
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2015-01-05 | Moderna | Alexion Pharmaceuticals investment in Series E - Moderna | 450 M USD |
| 2014-01-14 | Moderna | Alexion Pharmaceuticals investment in Corporate Round - Moderna | 25 M USD |
Key Employee Changes
| Date | New article |
|---|---|
| 2020-08-06 | Alexion hires first chief diversity officer, following pharma peers and social sentiment |
| 2020-02-04 | Amylyx Pharmaceuticals Appoints Jeffrey Trigilio Chief Financial Officer |
Official Site Inspections
http://www.alexion.com Semrush global rank: 530.26 K Semrush visits lastest month: 64.27 K
- Host name: server-18-67-65-116.iad89.r.cloudfront.net
- IP address: 18.67.65.116
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Alexion Pharmaceuticals"
About - Alexion
At Alexion, our passion drives us to continuously innovate and create meaningful value in all we do. In doing so, we change lives for the better – ours, people living with rare diseases, and the communities we serve. Every day. 3000+ …See details»
Our Science - Alexion
Driving Alexion’s Leadership in Rare Disease. Moshe Vardi, M.D., Vice President, Global Medicine Team Lead. Moshe is advancing the next wave of complement research as the head …See details»
Alexion Pharmaceuticals - Wikipedia
Alexion Pharmaceuticals was founded in 1992 at Science Park in New Haven, Connecticut by Steven Squinto and Leonard Bell, a physician at Yale New Haven Hospital and assistant professor of medicine and pathology at Yale School of Medicine. In 2000, Alexion moved its headquarters from New Haven to Cheshire, Connecticut. Alexion received U.S. Food and Drug Administration (FDA) approval for Soliris in 2007. It was ini…See details»
About Us - Alexion
By creating an unparalleled employee experience, our organization is equipped to adapt to and enrich employees with a productive, engaging, and enjoyable work experience while accelerating world-class leadership and innovation …See details»
Alexion Pharmaceuticals, Inc. | LinkedIn
Alexion, AstraZeneca Rare Disease was created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. by AstraZeneca. For more than 30 years, Alexion’s mission has been to transform the ...See details»
Working at Alexion
Alexion has more than 5,000 employees around the globe and serves patients in more than 50 countries. There are limitless opportunities for talented individuals to work across functions and geographies, taking on new challenges to …See details»
Alexion, AstraZeneca Rare Disease - BIO International Convention
Alexion, AstraZeneca’s Rare Disease group, was created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. For more than 30 years, Alexion’s mission has been to transform the …See details»
Leadership: Management and Board of Directors
Meet Alexion's Management Team and Board of Directors. LEADERSHIP Guiding Us to a Better Future, Every Day Management Team. Our management team is a talented, diverse, and experienced group of leaders who bring vast …See details»
Alexion Charitable Foundation Announces First Rare Belonging® …
The Alexion Charitable Foundation’s grant to Global Genes will support organizational members of the Global Genes RARE Foundation Alliance, as well as patients, caregivers and siblings …See details»
Alexion Strengthens and Broadens Its Executive Leadership Team
Clare Carmichael joined Alexion in 2011 and has markedly impacted Alexion's ability to grow our organization across an expanding and large global platform at a rapid rate with the highest …See details»
Working Every Day for the Rare Disease Community | Alexion ...
Feb 20, 2023 At Alexion, AstraZeneca Rare Disease, we are committed to working with the patient community and health care stakeholders worldwide to address these challenges. As is …See details»
Org Chart Alexion Pharmaceuticals - The Official Board
The organizational chart of Alexion Pharmaceuticals displays its 46 main executives including Marc Dunoyer, Sean Christie and Shane Doyle. Toggle navigation The Official Board. Search. …See details»
Canada - Alexion
Alexion is committed to serving people affected by rare diseases through the discovery, development and access of life-changing medicines. Our goal is to bring safe and effective …See details»
Alexion Canada Raises Awareness for Rare Diseases Through …
Feb 26, 2024 Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, is marking Rare Disease Day on February 29 by launching colourUp4RARE. The international campaign …See details»
Diversity - Alexion
Giving Back. Alexion embraces the communities in which we operate. To help tackle pressing social needs in our communities, we support non-profit organizations with monetary grants …See details»
Alexion Charitable Foundation | Alexion
We do this through two main impact areas: the Alexion Charitable Foundation and Corporate Giving. The signature program through which we provide funding from the Alexion Charitable …See details»
Alexion Announces Executive Leadership Changes
NEW HAVEN, Conn.--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced the following changes to its executive leadership team: Brian Goff is joining …See details»
History - Alexion
Alexion has grown from a biotech startup to a leading global biopharmaceutical company focused on rare disease. View milestones that have marked our growth.See details»
Alexion Reports Fourth Quarter and Full Year 2020 Results
Information about Alexion’s directors and executive officers is available in Alexion’s proxy statement for its 2020 annual meeting of stockholders, which was filed with the SEC on March …See details»